Behavioral problems in primary progressive aphasia
Rosen et al. found that semantic dementia is associated with significantly more behavioral dysfunction than other variants of primary progressive aphasia, and that the behavioral problems are similar to those seen in FTD.

Atrophy of the speech network in mutism
Gorno-Tempini et al. used voxel-based morphometry on MRI scans of patients with progressive nonfluent aphasia (PNFA). The authors showed that patients with PNFA who presented with early complete loss of speech had greater gray matter atrophy in left pars opercularis of Broca’s area and basal ganglia vs patients with PNFA who retained speech abilities, and healthy controls.

Targeting Aβ with 3-amino-1 propanesulfonic acid in AD
Aisen et al. assessed the safety, tolerability, and pharmacokinetic/pharmacodynamic profile of 3-amino-1 propanesulfonic acid (3APS), a novel anti-amyloid compound in AD. 3APS demonstrated a satisfactory safety and tolerability profile and reduced CSF Aβ42 concentrations in patients. Results support the pharmacologic and potential therapeutic effects of 3APS on disease progression.

Familial dystonia with cerebellar atrophy
Le Ber et al. report an unusual “dystonia plus” phenotype in eight families characterized by spasmodic dysphonia and upper limb dystonia. Mean age at onset was 27 years. The paucity of cerebellar signs contrasted with marked and global cerebellar atrophy.

Driving ability of patients with PD
Uc et al. found that drivers with PD were more likely to experience worsening of driving safety errors during an auditory-verbal distraction task on a freeway in an instrumented vehicle vs controls. Measures of cognition, motor function, and sleepiness predicted effects of distraction on driving performance within the PD group.

Deep brain stimulation and hypotension in PD
Stemper et al. analyzed orthostatic regulation in 14 patients with PD who had bilateral STN stimulators. The authors report that STN stimulation increased peripheral vasoconstriction and baroreflex sensitivity and stabilized blood pressure.
**LRRK2 mutations in early onset PD**

Clark et al. found an association of G2019S mutation with both early and late-onset PD, confirming the higher frequency of G2019S in Jewish than in non-Jewish cases, especially those with a family history of PD. They estimate penetrance in predicted carrier relatives to be 24.0% (95% CI: 13.5% to 43.7%).

see page 1786

**Pregabalin and neuropathic spinal cord injury pain**

In a large, randomized controlled trial in people with central neuropathic pain following spinal cord injury, Siddall et al. found that pregabalin significantly improved pain, sleep, and anxiety and overall status vs placebo.

see page 1792

**Prediction of thrombolytic efficacy by CT**

Kim et al. used thin-section noncontrast CT to estimate thrombus composition based on Hounsfield Units. Thrombi with lower Hounsfield Units were resistant to thrombolysis in acute ischemic stroke.

see page 1846

**Incidence of cervical artery dissection**

Lee et al. report the average annual incidence of dissections in a population-based study. Internal carotid artery dissection was detected approximately twice as frequently as vertebral artery dissection in the overall study, but in the latter half of the study period, vertebral artery and internal carotid artery dissection incidence rates were equivalent. The majority of cervical artery dissection patients in the community have excellent outcome, and contrary to many tertiary referral series, re-dissection is rare.

see page 1809

**Laser identifies loss of optic nerve fibers in AD**

Danesh-Meyer et al. found that compared to controls, patients with AD had an OR of 4.7 (95% CI: 2.3 to 9.8) for having a larger cup:disc ratio when the optic nerve head was measured with confocal scanning laser ophthalmoscopy (CSLO).

see page 1852

The editorial by Neil R. Miller and David Drachman notes the observation that retinal ganglion cells and optic nerve fibers may be lost in AD, which raises three questions: Could CSLO or OCT serve as a marker for the diagnosis of AD or as a surrogate for severity of AD in clinical trials? Does retinal ganglion cell and optic nerve fiber loss indicate that AD is a widespread, generalized brain disorder that is not confined to the mesial temporal region and is not exclusively a dementia? What insight can retinal ganglion cell and optic nerve fiber pathology provide about the mechanisms of AD? Their review considers these, noting that while one might expect to see the hallmark pathology of AD—neurofibrillary tangles and neuritic plaques in the retina—these classic neuropathologic features of AD are notably absent in retinal tissue. This suggests that beta amyloid and tau protein may not be the prime cause of neuronal and nerve fiber degeneration in AD.

see page 1742

**Study of pirfenidone in adults with neurofibromatosis type 1**

Babovic-Vuksanovic et al. studied the effect of pirfenidone in 24 patients with neurofibromatosis type 1, using three-dimensional MRI to assess outcome. At the end of treatment, four patients had a decrease in tumor volume by 15% or more, three had tumor progression, and 17/24 remained stable.

see page 1860

**Early vs delayed treatment of seizures**

The Marson et al. randomized multicenter study of early epilepsy and single seizures provides evidence of an effect for carbamazepine as monotherapy in delaying time to first seizure recurrence, but mixed evidence of an effect for valproate. Immediate treatment was superior to delayed treatment, and remission rates at 1-, 3-, and 5-year time points were similar for the two drugs.

see page 1872